Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Chronic inflammatory demyelinating polyneuropathy

Other Names for this Disease
  • CIDP
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

My friend was diagnosed with chronic inflammatory demyelinating polyneuropathy several months ago. He has been treated with platelet transfusions and gabapentin without relief. Are there other options for treatment? What is the outlook for this condition?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

How might chronic inflammatory demyelinating polyneuropathy (CIDP) be treated?

Treatment for CIDP includes:[1][2]  


  • Corticosteroids such as prednisone to help reduce inflammation and relieve symptoms
  • Medications that suppress the immune system (azathioprine, methotrexate, mycophenolate, cyclosporine, and cyclophosphamide)
  • Removal of antibodies from the blood through plasmapheresis or plasma exchange
  • Intravenous immunoglobulin (IVIg) therapy, which adds large numbers of antibodies to the blood plasma to reduce the effect of the antibodies 
  • Physiotherapy to improve muscle strength, function and mobility, and minimize the shrinkage of muscles and tendons and distortions of the joints


Detailed information about management options can be accessed through the Treatment and Medication sections of Medscape Reference.
Last updated: 8/1/2012

What is the long-term outlook for people with chronic inflammatory demyelinating polyneuropathy (CIDP)?

The course of CIDP varies widely among individuals. Some may have a bout of CIDP followed by spontaneous recovery, while others may have many bouts with partial recovery in between relapses. The disease is a treatable cause of acquired neuropathy and initiation of early treatment to prevent loss of nerve axons is recommended. However, some individuals are left with some residual numbness or weakness.[1]
Last updated: 8/1/2012